14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors

14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors

Neoplasia ("new growth") refers to an abnormal, uncontrolled, uncoordinated proliferation of cells that persists even after the cessation of the initiating stimulus. Neoplastic transformation results from accumulated genetic mutations that alter proto-oncogenes, tumor suppressor genes, and DNA repair pathways. Master knowledge of tumor classification, molecular oncogenesis, and paraneoplastic syndromes is vital for NPLEX Part I success.

Benign vs. Malignant Neoplasms: Classification and Features

Neoplasms are divided into benign and malignant categories based on their histological differentiation, growth kinetics, local invasiveness, and metastatic capability.

Neoplastic Nomenclature Rules

Tumors are named according to their parenchymal cell origin and histological pattern:

• Epithelial Origin:
  • Benign: Adenoma (glandular pattern), Papilloma (finger-like epithelial projections).
  • Malignant: Adenocarcinoma (malignant glandular tissue), Squamous Cell Carcinoma (malignant squamous epithelium).
• Mesenchymal Origin (Connective Tissue, Muscle, Bone):
  • Benign: Fibroma (fibrous tissue), Leiomyoma (smooth muscle), Lipoma (adipose tissue).
  • Malignant: Fibrosarcoma (malignant fibrous tissue), Leiomyosarcoma (malignant smooth muscle), Osteosarcoma (malignant bone).

Cytological Features of Anaplasia

Anaplasia ("to form backward") is the hallmark of high-grade malignancy. Histological characteristics include:

1. Pleomorphism: Extreme variation in cellular size and shape.
2. Hyperchromatic Nuclei: Darkly stained nuclei with coarsely clumped chromatin.
3. High N:C Ratio: Increased nuclear-to-cytoplasmic ratio approaching 1:1 (normal is 1:4 or 1:6).
4. Prominent Nucleoli: Abnormally large or multiple nucleoli.
5. Atypical Mitoses: Abnormal mitotic figures (e.g., tripolar or quadripolar spindles).

---

Molecular Hallmarks of Cancer

Hanahan and Weinberg outlined the essential cellular adaptations required for malignant transformation:

                            Sustained Proliferative Signaling
                                           \u2502
                            Evading Growth Suppressors (Rb/p53)
                                           \u2502
                             Resisting Cell Death (Apoptosis)
                                           \u2502
                           Limitless Replicative Potential (Telomerase)
                                           \u2502
                           Inducing Angiogenesis (VEGF)
                                           \u2502
                      Activating Invasion & Metastasis (Loss of E-Cadherin)
                                           \u2502
                     Reprogramming Energy Metabolism (Warburg Effect)
                                           \u2502
                         Evading Immune Destruction (PD-L1)

• Tissue Invasion and Metastasis: Occurs in a defined sequence:
  1. Downregulation of E-cadherin, loosening intercellular attachments.
  2. Attachment to basement membrane laminin.
  3. Degradation of basement membrane matrix via Type IV collagenases (MMP-2 and MMP-9).
  4. Migration through vascular walls and survival in circulation.
• The Warburg Effect: Cancer cells preferentially utilize aerobic glycolysis (converting glucose to lactate even in the presence of abundant oxygen) to generate metabolic intermediates required for rapid biomass assembly.

---

Oncogenes: Gain-of-Function Driver Mutations

Proto-oncogenes are normal physiological genes involved in cell growth and division. When mutated into oncogenes, a single allele gain-of-function mutation (dominant effect) drives persistent, unregulated cellular proliferation.

---

Tumor Suppressor Genes: Loss-of-Function Mutations

Tumor suppressor genes regulate cell cycle checkpoints, promote apoptosis, or repair damaged DNA. Tumor suppressors obey Knudson\u2019s Two-Hit Hypothesis: both alleles must be inactivated (loss-of-function, recessive effect) to promote oncogenesis.

       Normal Alleles (TSG+/TSG+) \u2500\u2500\u2500> First Hit (Germline or Somatic Mutation)
                                                    \u2502
                                                    \u25bc
                                      Heterozygous (TSG+/TSG-)
                                                    \u2502
                                      Second Hit (Somatic Deletion/Mutation)
                                                    \u2502
                                                    \u25bc
                                      Nullizygous Loss of Function
                                                    \u2502
                                                    \u25bc
                                        Uncontrolled Proliferation

Major Tumor Suppressors and Syndromes

1. TP53 (p53 \u2014 "Guardian of the Genome"):
   • Mechanism: DNA damage activates p53, which induces p21 (CDK inhibitor) to arrest the cell cycle at the G1/S checkpoint for DNA repair. If repair fails, p53 upregulates Bax to trigger apoptosis.
   • Syndrome: Li-Fraumeni Syndrome (inherited germline mutation causing multiple early-onset carcinomas and sarcomas).
2. RB1 (Retinoblastoma Gene):
   • Mechanism: Hypophosphorylated Rb protein binds and sequesters the E2F transcription factor, blocking G1 -> S progression. Phosphorylation of Rb by cyclin D/CDK4/6 releases E2F, advancing the cell cycle.
   • Syndrome: Familial Retinoblastoma (bilateral ocular tumors) and Osteosarcoma.
3. APC (Adenomatous Polyposis Coli):
   • Mechanism: Degradation complex protein that breaks down beta-catenin, inhibiting Wnt signaling.
   • Syndrome: Familial Adenomatous Polyposis (FAP) (thousands of colonic polyps progressing to colon adenocarcinoma).
4. BRCA1 and BRCA2:
   • Mechanism: Proteins involved in homologous recombination repair of DNA double-strand breaks.
   • Syndrome: Hereditary Breast and Ovarian Cancer syndrome (BRCA1 carries high risk for serous ovarian carcinoma).
5. VHL (Von Hippel-Lindau):
   • Mechanism: Ubiquitin ligase component that targets HIF-1-alpha (hypoxia-inducible factor) for degradation. Loss leads to constitutive HIF-1-alpha activation and VEGF expression.
   • Syndrome: Clear cell Renal Cell Carcinoma, cerebellar hemangioblastomas, and pheochromocytomas.
6. WT1: Wilms Tumor (pediatric renal neoplasm).
7. NF1 & NF2: Neurofibromatosis Type 1 (neurofibromin protein, Ras-GAP activator) and Neurofibromatosis Type 2 (Merlin protein, bilateral acoustic neuromas).

---

Paraneoplastic Syndromes

Paraneoplastic syndromes are systemic signs or symptoms caused by tumor secretion of functional hormones or peptides, or by cross-reactive antibodies, rather than local tumor invasion or metastasis.